Jasper Therapeutics, Inc. (JSPR)
| Previous close | 1.9900 |
| Open | 1.9700 |
| Bid | 1.9500 x 1100 |
| Ask | 1.9600 x 1100 |
| Day's range | 1.8901 - 1.9750 |
| 52-week range | 0.3860 - 4.6200 |
| Volume | |
| Avg. volume | 4,143,998 |
| Market cap | 196.13M |
| Beta (5Y monthly) | 2.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8070 |
| Earnings date | 10 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.38 |
- GlobeNewswire
Jasper Therapeutics to Present at Upcoming Conferences
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that the Company will be participating in the following conferences in March. William Blair’s Innovator Serie
- GlobeNewswire
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update
Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous UrticariaPresentation of Key Briquilimab Clinical Data, Including Initial Results in Stem Cell Transplant for Sickle Cell Disease and One Year Follow-Up for Acute Myeloid Leukemia Transplant PatientsRaised $101.4 Million Net Proceeds in January 2023 REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focu
- GlobeNewswire
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors
REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of healthcare industry veteran Vishal Kapoor, Partner of Avego Management, to Jasper’
